5913

AstraZeneca Pharmaceuticals agreed to pay 68.5 million to settle multistate litigation alleging unfair and deceptive practices in its marketing of the antipsychotic drug Seroquel, including promotion of the drug for unapproved uses, failure to adequately disclose potential side effects to health care providers, and withholding of scientific studies that called into question the drug's safety and efficacy.